Diabetic foot ulcers (DFUs) affect 15% of diabetic patients over their lifetime and are responsible for 85% of non-traumatic lower-extremity amputations. Annual DFU-related healthcare costs exceed $9 billion in the United States. The pathophysiology — peripheral neuropathy eliminating protective sensation, peripheral arterial disease compromising perfusion, and impaired immune function slowing healing — creates wounds that progress rapidly from superficial to limb-threatening without appropriate management. Our wound care catalog includes the complete range of DFU-specific products including silver antimicrobials, foam dressings, collagen matrices, and offloading devices.
Wound Bed Preparation: The TIME Framework
Wound bed preparation for DFUs follows the TIME framework: Tissue (necrotic/non-viable tissue removal by sharp, enzymatic, autolytic, or biological debridement); Infection/Inflammation (identify and treat biofilm, local infection, spreading cellulitis, or osteomyelitis); Moisture balance (manage exudate to maintain moist wound environment without maceration); Edge advancement (assess epithelial migration — non-advancing edges after 4 weeks require advanced therapy escalation). Sharp debridement — mechanical removal of necrotic tissue, callus, and eschar using scalpel or scissors — is the most effective debridement modality and should be performed at every DFU visit, even when the wound appears to be healing.
Offloading: The Most Underutilized Evidence-Based Therapy
Pressure offloading is the single most impactful intervention for plantar DFU healing — yet non-removable casting, the gold standard therapy (total contact cast, TCC), remains dramatically underutilized. Randomized trials consistently show TCC heals plantar DFUs in 6–8 weeks vs 12+ weeks for removable devices, because compliance is enforced. Knee-high irremovable cast walkers (instant TCC) provide comparable outcomes to traditional plaster TCC with faster application. Removable cast walkers are an acceptable alternative only when combined with adherence monitoring. Offloading sandals, healing shoes, and ankle-foot orthoses are appropriate for heel and non-plantar wounds. Healix stocks orthopedic and rehabilitation supplies at our orthopedic catalog.
Infection Management
DFU infection is classified by IDSA severity: mild (superficial, local only), moderate (deeper tissue involvement or systemic signs), and severe (systemic sepsis or limb-threatening). Mild infections are treated with oral antibiotics and antimicrobial wound dressings — silver-containing products (silver alginate, silver foam, ionic silver contact layers) are appropriate for critically colonized or mildly infected wounds. Moderate-to-severe infections require parenteral antibiotics, imaging to exclude osteomyelitis (MRI is gold standard — bone scan for implant contraindication), and potential surgical debridement. Osteomyelitis in DFU may require 6-week IV antibiotic courses or surgical bone resection.
Advanced Wound Products: When Standard Care Fails
IWGDF guidelines recommend escalation to advanced wound products when DFUs fail to reduce by ≥50% in area after 4 weeks of standard care. Evidence-based advanced therapies include: living skin equivalents (Apligraf, Dermagraft), acellular dermal matrices (Integra, MatriStem), platelet-rich plasma, NPWT, and hyperbaric oxygen therapy (for ischemic DFUs with ABI >0.5). Our wound care section and OR catalog carry NPWT devices and wound care accessories supporting DFU management at every stage.
